Background: We have previously reported algorithms which combine urine and plasma biomarkers to provide diagnostic information regarding a decision to perform a prostate biopsy and biologic stratification of aggressive prostate cancer (PCa). We expanded our biomarker panel to explore the potential of incorporating androgen receptor (AR) and PTEN expression levels in urine and plasma to improve our algorithms' ability to: 1) Determine the presence of PCa in patients with presumed benign prostate hyperplasia (BPH), and to: 2) Distinguish high-vs. low-risk PCa.
